AstraZeneca Inks $1.5B Sale Of US Respiratory Drug Rights
AstraZeneca will sell the U.S. rights to a respiratory drug to Sobi for $1.5 billion in cash and stock up front as part of a push to streamline its portfolio of...To view the full article, register now.
Already a subscriber? Click here to view full article